October 20, 2011
AURORA, Ontario, October 20, 2011 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), today announced that it
has terminated its Financial and Investor Relations Agreement with ACM Alpha Consulting Management Est. (ACM) for
cause due to breaches of the agreement which have recently come to Helix’s attention. Under the Agreement, ACM and its
agents (including Andreas Kandziora) provided Helix with various investor and financial advisory services in Europe. ACM
and its agents are no longer providing any such services to Helix, and do not represent Helix in any capacity.